Tested Applications
| Positive FC detected in | human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| Flow Cytometry (FC) | FC : 5 ul per 10^6 cells in 100 μl suspension |
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 μl per 10^6 cells in a 100 µl suspension or 5 μl per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
FITC-65109 targets CD45 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Mouse / IgG1, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
Human peripheral blood leucocytes Predict reactive species |
| Full Name | protein tyrosine phosphatase, receptor type, C |
| GenBank Accession Number | BC014239 |
| Gene Symbol | CD45 |
| Gene ID (NCBI) | 5788 |
| ENSEMBL Gene ID | ENSG00000081237 |
| RRID | AB_2883780 |
| Conjugate | FITC Plus Fluorescent Dye |
| Excitation/Emission Maxima Wavelengths | 495 nm / 524 nm |
| Excitation Laser | Blue laser (488 nm) |
| Form | Liquid |
| Purification Method | Affinity purification |
| UNIPROT ID | P08575 |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
CD45, also known as protein tyrosine phosphatase, receptor type C, is a type I transmembrane protein expressed on the surface of all haematopoietic cells with the exception of erythrocytes and platelets (PMID: 3489673; 28615666). CD45 is a pan-haematopoietic cell marker and has been shown to be essential for T- and B-cell activation and signalling (PMID: 9429890; 16378097).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for FITC Plus CD45 antibody FITC-65109 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
FITC-65109 has 7 total citations across journals including Blood, Advanced Science, Cells, Frontiers in Bioengineering and Biotechnology, FASEB Journal, and Archives of Dermatological Research. Research fields span acute myeloid leukemia epigenetics, antitumor bispecific antibody delivery, ovarian cancer peritoneal metastasis, bone regeneration, osteonecrosis of the femoral head, T-cell acute lymphoblastic leukemia progression, and m6A-mediated dermal fibroblast proliferation. All citations used flow cytometry as the application.
| Species | Application | Title |
|---|---|---|
Blood Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia | ||
Adv Sci (Weinh) Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors | ||
Cells Exosomes from Human Omental Adipose-Derived Mesenchymal Stem Cells Secreted into Ascites Promote Peritoneal Metastasis of Epithelial Ovarian Cancer | ||
Front Bioeng Biotechnol Self-assembled microtissues loaded with osteogenic MSCs for in vivo bone regeneration | ||
Front Bioeng Biotechnol Suppression of exosomal miR-199a-3p, a differentially expressed miRNA in steroid-induced osteonecrosis of the femoral head, promotes cell proliferation, osteogenesis, and angiogenesis while inhibiting dexamethasone-induced apoptosis. | ||
FASEB J TARDBP drives T-cell acute lymphoblastic leukemia progression by binding MDM2 mRNA, involving β-catenin pathway |
